<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01279915</url>
  </required_header>
  <id_info>
    <org_study_id>0456-CL-0011</org_study_id>
    <nct_id>NCT01279915</nct_id>
  </id_info>
  <brief_title>A Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects</brief_title>
  <official_title>Phase I Study of ASP0456 - A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Non-elderly Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single
      ascending dose of ASP0456 in non-elderly healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP0456 assessed by its plasma concentration change</measure>
    <time_frame>For 48 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, 12-lead ECGs and labo tests</measure>
    <time_frame>For 48 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of ASP0456</condition>
  <arm_group>
    <arm_group_label>ASP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP0456 receiving group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP0456</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP group</arm_group_label>
    <other_name>linaclotide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, as judged by the investigator/subinvestigator based on the results of
             physical examination and all tests obtained

          -  Body weight (at screening); ≥50.0 kg,&lt;80.0 kg

          -  BMI(at screening): ≥17.6,&lt;26.4

        Exclusion Criteria:

          -  Received any investigational drugs in other clinical or post-marketing studies within
             120 days before the study

          -  Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or
             blood components within 14 days before the study

          -  Received medication within 10 days before dose is administered or is scheduled to
             receive medication

          -  History of drug allergies

          -  Upper (e.g. nausea, vomiting, stomachache) and lower (e.g. abdominal pain)
             gastrointestinal disease within 7 days before the study

          -  Concurrent or previous hepatic disease

          -  Concurrent or previous heart disease

          -  Concurrent or previous renal disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <last_update_submitted>January 18, 2011</last_update_submitted>
  <last_update_submitted_qc>January 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Astellas Pharma, Inc</organization>
  </responsible_party>
  <keyword>ASP0456</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

